AEON Biopharma (NASDAQ:AEON – Free Report) had its price objective reduced by HC Wainwright from $18.00 to $6.00 in a research report sent to investors on Wednesday, Benzinga reports. They currently have a buy rating on the stock. AEON Biopharma Stock Down 2.5 % AEON traded down $0.04 during midday trading on Wednesday, reaching $1.54. […]